Following an application by the Royal College of Pathologists of Australasia (RCPA) to the Medical Services Advisory Committee (MSAC), reproductive carrier screening for fragile X syndrome (FXS), spinal muscular atrophy (SMA) and cystic fibrosis (CF) will be listed on the Medicare Benefits Schedule (MBS). The funding forms part of the 2022/23 Federal Budget which is being announced this week.